Degarelix

Overview

Degarelix, marketed as Firmagon, is a synthetic GnRH antagonist used in the treatment of advanced prostate cancer. It is given as a subcutaneous injection by a healthcare professional. Unlike the GnRH agonists such as goserelin, triptorelin, and leuprolide, degarelix blocks GnRH receptors directly.

The most clinically important distinction is that degarelix produces no initial testosterone flare. Because it does not first stimulate the pituitary, testosterone falls rapidly from the start of treatment, without the early surge seen with agonists. This makes it particularly relevant for men in whom a flare could be problematic.

By suppressing testosterone, degarelix serves as a form of androgen deprivation therapy, reducing the hormonal stimulation that hormone-sensitive prostate cancers depend on for growth.

How it works

Testosterone production depends on pituitary release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are driven by GnRH from the hypothalamus. Both GnRH agonists and antagonists ultimately lower testosterone, but they do so differently.

GnRH agonists first overstimulate the pituitary, causing a temporary testosterone surge (the flare) before desensitization brings levels down. Degarelix, as an antagonist, binds GnRH receptors and blocks them immediately, with no initial stimulation. LH and FSH fall promptly, and testosterone drops to castrate-range levels rapidly, often within days.

Because there is no flare, degarelix does not typically require an accompanying anti-androgen to cover an early surge, a notable practical contrast with agonists. The testosterone suppression is reversible, with levels recovering after treatment is stopped.

Clinical evidence

Degarelix has been studied as androgen deprivation therapy in advanced prostate cancer, with clinical development programs comparing it against GnRH agonist therapy such as leuprolide. A consistent finding is that degarelix achieves faster testosterone suppression without the initial flare characteristic of agonists.

Research has also explored differences in testosterone control and other outcome measures between antagonist and agonist therapy. The clearest and most established advantage of degarelix is the avoidance of the flare, which is clinically meaningful for men at risk of complications from a transient testosterone rise, such as those with significant disease burden.

As with other forms of androgen deprivation, the choice between an antagonist and an agonist depends on individual factors, disease characteristics, and clinician judgment. Treatment decisions weigh the benefits of rapid, flare-free suppression against side effects and practical considerations.

Dosing & side effects

Degarelix is given as a subcutaneous injection by a healthcare professional, typically starting with an initial loading approach followed by maintenance, with the specifics determined by the clinician. This page does not provide dosing instructions.

Side effects largely result from low testosterone and may include hot flashes, weight changes, fatigue, reduced libido, and sexual dysfunction. Reduced bone mineral density can occur with prolonged therapy, and metabolic and cardiovascular factors may be monitored. A notably common issue with degarelix is injection-site reactions, such as redness, pain, or swelling, which are often most pronounced early in treatment.

Because degarelix is an antagonist, it does not cause an initial testosterone flare, so the early symptom worsening sometimes seen with agonists is avoided, and an anti-androgen for flare protection is generally not needed. Patients should discuss monitoring with their care team.

Legal status

Degarelix is an FDA-approved prescription medication for advanced prostate cancer and is approved by regulators in many other countries. It is administered under medical supervision by trained professionals.

It is not available over the counter and is not intended for self-administration or non-medical use. Its approved indication and use are defined by regulatory authorities and product labeling.

Because degarelix requires professional administration, careful patient selection, and ongoing monitoring, it should be obtained only through legitimate medical channels and used under specialist guidance.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Zengerling F, Jakob JJ, Schmidt S, et al. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021. Peer-reviewed study
2. Devos G, Tosco L, Baldewijns M, et al. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer. Eur Urol. 2023. Peer-reviewed study
3. Lopes RD, Higano CS, Slovin SF, et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation. 2021. Peer-reviewed study
4. Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs. 2009. Peer-reviewed study
5. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008. Peer-reviewed study
6. Carter NJ, Keam SJ. Degarelix: a review of its use in patients with prostate cancer. Drugs. 2014. Peer-reviewed study